Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 24, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

Enzalutamide

Second-generation androgen pathway inhibitor (ARAT), oral tablet

OTHER

Standard of Care SBRT and ADT

Standard of care stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT)

Trial Locations (2)

M5G 2M9

RECRUITING

Princess Margaret Cancer Center, Toronto

M4N 3M5

ACTIVE_NOT_RECRUITING

Sunnybrook Research Institute, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

University Health Network, Toronto

OTHER